

 <p>Financial Assistance Award</p> <p>DENALI COMMISSION 510 L Street, Suite 410 Anchorage, Alaska 99501 (907) 271-1414 (phone) (907) 271-1415 (fax) www.denali.gov</p>		Award Number	01513-01		
		Award Title	Respiratory Syncytial Virus (RSV) Study		
		Performance Period	October 1, 2016 through June 30, 2019		
Authority 112 Stat 1854	CFDA Number 90.100	<u>Recipient Organization & Address</u> Yukon Kuskokwim Health Corporation PO BOX 528 Bethel, AK 99559-0528 Phone: [NoPhoneRecord] Recipient DUNS # 082508961 TIN # 920041414			
Denali Commission Finance Officer Certification					
<u>Cost Share Distribution Table</u>					
Accounting Code	New Funding		Prior Period Funding		Total
	Denali Commission	Other Contributors	Denali Commission	Other Contributors	
95670000	\$36,765.28		\$334,780.00		\$371,545.28
	\$0.00		\$0.00		\$0.00
	\$0.00		\$0.00		\$0.00
	\$0.00		\$0.00		\$0.00
	\$0.00		\$0.00		\$0.00
		\$0.00		\$0.00	\$0.00
		\$0.00		\$0.00	\$0.00
		\$0.00		\$0.00	\$0.00
		\$0.00		\$0.00	\$0.00
Total	\$36,765.28	\$0.00	\$334,780.00	\$0.00	\$371,545.28
This Financial Assistance Award approved by the Federal Co-Chair of the Denali Commission constitutes an obligation of federal funding.					
Signature of Authorized Official - Denali Commission Electronically Signed		Typed Name and Title Mr. Jay Farmwald Director of Programs		Date 10/11/2018	

AWARD ATTACHMENTS

Yukon Kuskokwim Health Corporation

01513-01

-
1. Terms and Conditions
 2. Attachment A
 3. Budget and Funding Summary
 4. Attachment B

*Financial Assistance Award No. 1513
Between the Denali Commission and Yukon Kuskokwim Health Corporation
For Respiratory Syncytial Virus Study
Amendment 1*

All changes to the award conditions are noted below.

1. Increase funding by \$36,765.28.
2. Change Denali Commission Program Manager to
Kristen Arnold
P: 907/271-5239
E: karnold@denali.gov
3. Extend the period of performance for this project to 30 June 2019.
4. Replace original Attachment A dated September 22, 2017 with revised Attachment A dated August 16, 2018.

**Attachment A
To The
Financial Assistance Award Terms and Conditions
Between the Denali Commission and Yukon Kuskokwim Health Corporation
For RSV Study
Award #1513 Amendment 1**

- a. Scope of Work: Reference Attachment B dated 1 August 2017
- b. Deliverables: Reference Attachment B dated 1 August 2017
- c. Budget: The Commission is making \$371,545.28 available for the project via this Financial Assistance Award (FAA). These funds were transferred to the Commission by the Centers For Disease Control (CDC) via an Interagency Agreement under the authority of MAP 21. Detailed budget and funding information is summarized on page 2.
- d. Delivery Method: Reference Attachment B dated 1 August 2017
- e. Schedule: The period of performance for this project is 1 October 2016 thru 30 June 2019. Key milestones are summarized below.

Start Study: 1 January 2017
Complete Study: 30 June 2019
Closeout Report: 30 September 2019

BUDGET				
Line	Item	By	Amount	Basis/Notes
1	Original Award			
2	Research Nurse	YKHC	113,963.00	0.5 FTE
3	Research Assistant	YKHC	40,955.00	0.5 FTE
4	Nurse and Assistant Fringe Benefits	YKHC	46,476.00	30% of lines 1 and 2
5	Investigator	ANTHC	19,344.00	0.1 FTE
6	Subtotal Salary		220,738.00	
7	Lab Test Supplies	YKHC	34,000.00	\$85/specimen x 200 tests/yr x 2 yrs
8	Participant Incentives	YKHC	14,000.00	400 each \$35 gift cards
9	Travel	ANTHC & CDC	6,000.00	2 trips @ \$3,000 each
10	Indirect Costs ^a	YKHC	60,041.00	27.2% of line 6 (allocation base per CDC budget dated 1 August 2016)
11	Total		\$334,779.00	
12	Amendment 1			
13	Research Coordinator	YKHC	15,610.00	.25 FTE
14	Investigator	ANTHC	15,100.00	.1 FTE
15	Subtotal Salary		30,710.00	
16	Travel	ANTHC	358.00	
17	Indirect Costs ^b	YKHC	4,182.48	26.8% of line 13
18	Indirect Costs ^c	ANTHC	1,515.80	26.8% of \$5,656
19	Total		36,766.28	
20				
21	Grand Total		\$371,545.28	

a. YKHC has a federally negotiated indirect rate of 27.2% dated 25 November 2014 thru 30 September 2015.

b. YKHC has a federally negotiated indirect rate of 26.8% dated 23 August 2015 thru 30 September 2017.

c. Per 2CFR200 and the FAA Terms & Conditions, YKHC can only charge IDC on the first \$25,000 of their subcontract/subaward with ANTHC: \$25,000 - \$19,344 (line 5) = \$5,656

d. When submitting for reimbursement, YKHC must use the approved IDC rate that was in effect at the time the direct costs were incurred.

FUNDING				
Line	Source	Reference	Amount	Notes
22	Denali Commission	1513.00	\$334,780.00	CDC funds provided to Commission via IAA - 16FED1612371
23	Denali Commission	Amendment 1	\$36,765.28	CDC funds provided to Commission via IAA - 16FED1612372 Amendment 001
24	Total Funding Available As Of This Action		\$371,545.28	
25	Program Balance*		\$2,533	\$334,780 + \$39,298.28 - \$371,545.28

* Difference between total program budgets prepared by CDC vs. the actual FAA budget/funding amounts shown above. The program balance will be reallocated at the discretion on the Denali Commission in consultation with CDC.

Attachment B
August, 1 2017

Interagency Agreement
Between
Centers for Disease Control and Prevention and
Denali Commission

IAA 16FED1612371 order 0001 Amendment 001

The purpose of this amendment to add \$40,084.25 to the current existing order 0001.

Title: Active surveillance for respiratory syncytial virus in hospitalized Alaska Native adults from the Yukon Kuskokwim Delta region.

Investigators: Rosalyn Singleton MD MPH, Karen Rudolph PhD, , Thomas Hennessy MD, Joseph Klejka MD, Prabhu Gounder MD, Michael Bruce MD, Lisa Bulkow MS, Susan Gerber, Janet Englund MD, Helen Y Chu MD, Larry Anderson MD. Arctic Investigations Program, YKHC, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control; CDC, OI, NCIRD; University of Washington, Emory University.

Background: Alaska Native infants from the Yukon Kuskokwim (YK) Delta region have the highest reported respiratory syncytial virus (RSV) –associated hospitalization rate reported in the United States; however, there is no information about the contribution of RSV to acute respiratory infection (ARI) or respiratory exacerbation hospitalizations in Alaska Native adults. Adults in YK Delta have a high rate of respiratory hospitalizations; 77% of preventable hospitalizations are respiratory exacerbations of COPD. Adult RSV vaccines are in late-phase clinical trials and information about the contribution of RSV to adult respiratory hospitalization in Alaska Native people are a prerequisite to help design vaccine trials.

Objectives: Our main objective is to evaluate the contribution of RSV to hospitalized respiratory illness/exacerbations in adults by determining the #/% of adult respiratory-related hospitalizations which are RSV positive. We will also determine the contribution of RSV to respiratory exacerbations of adults with COPD or bronchiectasis and compare to the contribution from influenza. Importantly, we will determine the overall hospitalization rate associated with RSV infection in Alaska Native adults with underlying disease conditions.

Methods: After informed consent, we will obtain a NP swab on YK Delta adults 19+ years hospitalized at YK Delta Regional Hospital (12 adult beds) or Alaska Native Medical Center (~140 adult beds) with a respiratory illness or COPD exacerbation. NP swabs will be tested for RSV A and B as well as influenza A and B, parainfluenza, rhinovirus, coronavirus, adenovirus and human metapneumovirus using sensitive and specific reverse transcriptase singleplex polymerase chain reaction (PCR). We will swab consented adults weekly during hospitalization to evaluate duration of shedding, viral load and nosocomial spread of RSV. We will also conduct a short questionnaire of symptoms and perform a medical record review of hospitalizations, clinic visits and antibiotic use in the past 6 months and underlying conditions. We will also seek a waiver of informed consent to do a medical record review of a sample of de-identified adults 19-44 years, 45-64 years, and 65+ years of age to determine the proportion of YK Delta adults who have underlying medical conditions. Duration of project: We will conduct the study over a 2 year period. There are 75 bacterial pneumonia and 120 COPD exacerbation/asthma hospitalizations annually in YK Delta adults 19+ years, with an adult population of approximately 13,830.

Data Management: Denominator and basic hospital demographics for YK adults including length of stay will be obtained through census and YKDRH hospitalization data. Participant electronic health records will be reviewed for the current hospitalization duration and severity and for underlying medical conditions.

Analysis: Rates of LRTI and RSV hospitalization will be calculated and analysis performed for the following variables: age 19-49, 50-64, and 65+ years, sex, underlying COPD and other conditions, month of admission. The impact of viral load for each virus will be studied with respect to demographics including age, sex, severity of disease (mechanical

ventilation, duration). Antibody concentrations in the sera will be compared to disease severity based on ARI diagnosis, hospital stay, and mechanical ventilation. Decline in viral load will be assessed by weekly assessment of RSV viral load in patients hospitalized for > 1 week.

Budget: Modification 0001

<u>Budget Item</u>	<u>Location</u>	<u>Cost/year</u>
Personnel		
YK Research Coordinator	YKHC	\$15,610.00
ANTHC Investigator	ANTHC	\$15,100.00
Total salary		\$30,710.00
Indirect (26.8%)	YKHC	\$8,230.28
		\$38,940.28
Travel		
ANTHC investigator travel to YK	YKHC	\$358.00
Subtotal		
		<u>\$39,298.28</u>
Denali Commission (2%)		<u>\$785.97</u>
Total		\$40,084.25

Original budget order 0001

RSV Surveillance in hospitalized YK Adults - Budget

<u>Budget Item</u>	<u>Location</u>	<u>Total</u>
Personnel		
1/2 FTE YKHC Research Nurse	YKHC	\$113,963
1/2 FTE YKHC Research Asst	YKHC	\$40,955
Fringe benefits - Nurse and Asst	YKHC	\$46,476
1/10ANTHC Investigator	ANTHC	\$19,344
Total salary		\$220,740
Indirect (27.2%)	YKHC	\$60,040
Travel		
CDC Investigator travel to YK	CDC	\$3,000
ANTHC investigator travel to YK	YKHC	\$3,000
Laboratory Costs		
NP specimen testing (\$85/specimen x 200 specimen/yr)	YK purchase supplies	\$34,000
Study Participant Gift Cards		
\$35 per study participant x 400	YK purchase gift cards	\$14,000
Total		\$334,780
Subtotal		
Indirect		
Denali Commission (2%)		<u>\$6,696</u>
Total		\$341,476